Program
BL1107
A development code. Also written as “BL1107 Low dose” and “BL1107 High dose”.
Its studies are mostly in Dry Eye Syndromes · Glaucoma, led by Bausch Health Companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bausch Health Companies | 21 open or running | phase 2since Sep 5, 2025 | Sep 5, 2025 | Feb 2027phase 2 · NCT07778888 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 5, 2025First study: phase 2 study in GlaucomaFirst studyNCT07168902 · 252 enrolled · United States
- Aug 18, 2026Phase 2 study in Dry Eye SyndromesNCT07778888 · 20 planned · United States
Ahead
- Feb 2027Primary completion: phase 2 study in Dry Eye SyndromesNCT07778888
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07778888Dry Eye Syndromes · United States | 2 | Recruiting | Feb 2027 | 20 |
| NCT07168902Glaucoma · United States | 2 | Completed | May 18, 2026 | 252 |
How it is read
Names in the registry
- “BL1107”, 1 entry
- “BL1107 Low dose”, 1 entry
- “BL1107 High dose”, 1 entry
Codes read as this program: BL1107.
Conditions, from the studies’ own filings
- Dry Eye Syndromes, 1 study
- Glaucoma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.